Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease

Cardiology in Review
Joshua F ZeidnerRobert G Lerner

Abstract

Antiplatelet therapy for the prevention and treatment of coronary artery disease (CAD) has undergone dramatic changes and improvements. Aspirin remains the first-line antiplatelet drug for clinical use. Newer platelet inhibitors such as the thienopyridine agents, ticlopidine and clopidogrel, have also been shown to be effective in treating CAD. There have been ongoing efforts to evaluate newer antiplatelet drugs, with the potential to improve clinical efficacy and safety. Some of the more promising antiplatelet agents include new adenosine diphosphate receptor antagonists such as prasugrel, cangrelor, and ticagrelor (AZD6140). In addition, a new thromboxane receptor antagonist, NCX-4016, a newly discovered protease-activated receptor antagonist that targets thrombin-induced platelet aggregation, and anti-von Willebrand factor aptamers show tremendous promise in refining antiplatelet therapy by targeting different receptors and molecules.

References

Mar 17, 1999·The Journal of Clinical Investigation·M L KahnS R Coughlin
Aug 11, 2001·British Journal of Pharmacology·M N MuscaráJ L Wallace
Aug 25, 2001·The New England Journal of Medicine·S YusufUNKNOWN Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Jan 31, 2002·Proceedings of the National Academy of Sciences of the United States of America·Claudio NapoliLouis J Ignarro
Jul 11, 2002·Journal of the American College of Cardiology·Richard H HongoRupsa R Yee
Sep 19, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Stefano FiorucciSalvador Moncada
Nov 2, 2002·Nature Medicine·Zaverio M Ruggeri
Dec 15, 2004·Circulation·John A SpertusRandall C Thompson
Mar 11, 2005·The New England Journal of Medicine·Marc S SabatineUNKNOWN CLARITY-TIMI 28 Investigators
Sep 10, 2005·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Anders Bach NielsenClaus Larsen
Oct 4, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Yaqin XuZequan Yang
Nov 8, 2005·Lancet·Z M ChenUNKNOWN COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group
Dec 24, 2005·Cardiology in Review·Costas HanjisRobert G Lerner
Mar 18, 2006·Thrombosis and Haemostasis·Andrew D Blann
Apr 20, 2006·Current Opinion in Chemical Biology·Jennifer F LeeAndrew D Ellington
Apr 22, 2006·Cardiology in Review·Theresa NguyenRobert G Lerner
Sep 26, 2006·International Journal of Cardiology·Charalambos AntoniadesChristodoulos Stefanadis
Oct 10, 2006·International Journal of Cardiology·Roberto LorussoAndrea Giustina
Oct 19, 2006·Expert Opinion on Drug Safety·Glen E Cooke, Pascal J Goldschmidt-Clermont
Nov 14, 2006·The American Journal of Cardiology·Stephen D Wiviott
Dec 26, 2006·Expert Review of Cardiovascular Therapy·Marco Cattaneo
Jan 25, 2007·Expert Opinion on Investigational Drugs·Udaya S TantryPaul A Gurbel
May 15, 2007·Circulation Research·Telly A Meadows, Deepak L Bhatt
May 29, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Yilong FuYi Zhun Zhu
Jun 29, 2007·Thrombosis and Haemostasis·Kenneth J Clemetson
Nov 6, 2007·Journal of the American College of Cardiology·Paul A GurbelAlan D Michelson
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Nov 6, 2007·The New England Journal of Medicine·Deepak L Bhatt

❮ Previous
Next ❯

Citations

Feb 23, 2010·JACC. Cardiovascular Interventions·Ali O Abualsaud, Mark J Eisenberg
Jul 3, 2009·Pharmazie in unserer Zeit·Heiko Zettl, Manfred Schubert-Zsilavecz
Dec 21, 2014·Purinergic Signalling·Geoffrey Burnstock, Amir Pelleg
Oct 17, 2008·Cardiology in Review·Michael H KooWilliam H Frishman
Dec 18, 2013·Pharmacological Reviews·Geoffrey Burnstock, Vera Ralevic
Feb 4, 2012·Cardiology in Review·William H Frishman, Kalyana Pallerla

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.